Case Report

Primary CNS Lymphoma Arising from the 4th Ventricle: A Case Report and Review of the Literature

Ava Brozovich, Donald Ewing, Ethan Burns, Courtney Hatcher, Gonzalo Acosta, Usman Khan, Betty Chung, Leena Samuel, Jasleen Randhawa, and Sai Ravi Pingali

1Texas A&M University College of Medicine, 8441 Riverside Parkway, Bryan, TX 77807, USA
2Houston Methodist Hospital, Department of Medicine, 6550 Fannin St., Houston, TX 77030, USA
3Houston Methodist Hospital, Department of Pathology and Genomic Medicine, 6550 Fannin St., Houston, TX 77030, USA

Correspondence should be addressed to Ethan Burns; eaburns312@gmail.com

Received 11 December 2018; Revised 15 March 2019; Accepted 19 March 2019; Published 10 April 2019

1. Introduction

PCNSL is a rare form of extranodal NHL comprising 2.7-4.0% of central nervous system (CNS) tumors [1, 2], with an age-adjusted incidence rate of 4 cases per million persons per year [3]. PCNSL originates in the brain, leptomeninges, spinal cord, or eyes [4] and is morphologically indistinguishable from other sites of extranodal NHL [5]. The most common subtype is DLBCL, accounting for approximately 90% of PCNSLs [6]. While PCNSL is an infrequent diagnosis, rarer still is the diagnosis of intraventricular lymphoma, with a limited number of cases to contribute to the knowledge of clinical manifestations, diagnostic modalities, and optimal treatment [7–22]. The following case adds to the limited clinical knowledge of 4th ventricular PCNSL.

2. Case

A 65-year-old Caucasian male with a pertinent history of ischemic stroke, subarachnoid hemorrhage, and recent onset of simple partial seizures 2 months prior to admission presented with a 4-week history of worsening diplopia, vertigo, nausea, and vomiting. Magnetic resonance imaging (MRI) revealed a 2.5 × 1.8 × 1.7 cm posterior fossa mass arising from the roof of the 4th ventricle extending into the cerebellar vermis. Posterior fossa craniotomy with stereotactic biopsy confirmed a locally invasive diffuse large B-cell lymphoma (DLBCL). Primary central nervous system lymphoma (PCNSL) arising from the 4th ventricle is a rare extranodal manifestation of non-Hodgkin lymphoma (NHL), with few cases documented in the literature. Review of available cases lends support that lymphoma arising from the 4th ventricle has a variable clinical presentation, occurs most commonly in immunocompetent males, and should be on the differential of any immunocompetent adult presenting with a posterior fossa mass. Optimal treatment modalities are based largely on phase 2 clinical trials, and recommended guidelines regardless of anatomic location should be adhered to.
acuity bilaterally, and subtle bilateral dysmetria on finger-to-nose test. A complete neurologic exam was otherwise normal. Labs were unremarkable.

An MRI showed a $2.5 \times 1.8 \times 1.7$ cm homogenously enhancing mass that extended from the roof of the 4th ventricle (Figure 1). Perilesional edema was present without mass effect or obstructive hydrocephalus. The patient was started on dexamethasone and underwent a posterior fossa craniotomy with stereotactic biopsy that showed locally invasive disease extending from the roof of the 4th ventricle into the cerebellar vermis. Intraoperative frozen sectioning revealed sheet-like arrangements of highly pleomorphic lymphoid tumor cells with atypical mitotic figures and focal necrosis, suggestive of lymphoma. Permanent sections confirmed the findings and highlighted the diffuse and angiocentric nature of the lymphoma, which was comprised primarily of large-sized lymphoma cells (Figure 2). Relevant immunohistochemical staining was positive for CD45, CD20, CD79a, MUM-1, MIB-1 (Ki-67: 80% proliferation rate), Bcl-6, and Bcl-2 and negative for CD3, CD5, CD10, CD30, C-MYC, and EBER in situ hybridization. The final histopathologic diagnosis was DLBCL with a postgerminal center phenotype. The patient had peripheral blood flow cytometry with 1% clonal B cells coexpressing CD5 with surface kappa light chain restriction, possibly representing a monoclonal B cell lymphocytosis. Cerebrospinal fluid (CSF) flow cytometry was negative for malignancy. Lactate dehydrogenase (LDH) was within normal limits. Positron emission tomography (PET) indicated increased uptake (SUV of 19.3) in the 4th ventricular mass as well as a small focus of uptake in the right pituitary gland (Figure 3). Staging workup with computed tomography (CT) of the chest, abdomen, and pelvis, as well as whole body PET scan, was otherwise negative for metastasis.

The patient was initiated on rituximab, methotrexate, and cytarabine, followed by intrathecal methotrexate and a combination of cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), with plans for subsequent treatment with temozolomide and whole-brain radiation. After receiving his first dose of rituximab and methotrexate, he noted significant improvement in his symptoms. After his second cycle of Hyper-CVAD, repeat imaging showed resolution of the masses; he has been on single agent ibrutinib as maintenance therapy since and without recurrence for 10 months.

3. Discussion

In general, patients with PCNSL develop neurologic symptoms over the course of weeks to months. The symptoms depend on the site of involvement but can include focal neurologic deficits (56-70%), altered mental status (32-43%), symptoms related to elevated intracranial pressure

Figure 1: (a) Coronal T1 flair, postcontrast imaging 2 months prior to admission. No enhancing lesion seen. (b) Sagittal T1 flair, postcontrast imaging 2 months prior to admission. No enhancing lesion seen. (c) Coronal T1 flair, postcontrast imaging. There is a $1.7 \times 2.5 \times 1.8$ cm homogenously enhancing mass with mild perilesional edema. (d) Sagittal T1 flair, postcontrast imaging. There is a $1.7 \times 2.5 \times 1.8$ cm homogenously enhancing mass arising from the roof of the 4th ventricle invading into the cerebellar vermis.
Figure 2: Primary CNS lymphoma arising from the 4th ventricle. (a) Diffuse sheets of lymphoid tumor cells with focal necrosis, H&E stain, 40x magnification. (b) Large atypical tumor cells with angiocentric localization, H&E stain, 400x magnification. (c) CD20 immunostain, 400x magnification. (d) BCL-6 immunostain, 400x magnification. (e) MUM-1 immunostain, 400x magnification. (f) Ki-67 (MIB-1) immunostain (80% proliferation index), 400x magnification.

Figure 3: PET imaging of the brain showing increased uptake in the pituitary (a) and the posterior fossa (b). PET: positron emission tomography.
Table 1: Summary of findings in individuals with 4th ventricular central nervous system lymphoma, including age, sex, immune status at presentation, initial symptoms, lymphoma subtype, treatment, and survival [7–22].

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Age/sex</th>
<th>Immune status</th>
<th>Symptoms</th>
<th>Lymphoma subtype</th>
<th>Treatment</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Werneck et al., 1977 [7] *</td>
<td>17/F</td>
<td>IC</td>
<td>Meningeal signs</td>
<td>PCNSL</td>
<td>Resection</td>
<td>Postmortem diagnosis</td>
</tr>
<tr>
<td>Haegelen et al., 2001 [8]</td>
<td>33/F</td>
<td>IC</td>
<td>Headache, vertigo, and ataxia</td>
<td>High-grade BCL</td>
<td>Resection, chemoradiation, ITC, and aSCT</td>
<td>No recurrence at 7 months</td>
</tr>
<tr>
<td>Hill et al., 2009 [9]</td>
<td>69/M</td>
<td>IC</td>
<td>Vomiting, nausea, anorexia, and weight loss</td>
<td>DLBCL</td>
<td>Chemotherapy, ITC</td>
<td>No recurrence at 3 months</td>
</tr>
<tr>
<td>Brar et al., 2012 [10] \α</td>
<td>65/F</td>
<td>IC</td>
<td>Headache, nausea, and vomiting</td>
<td>High-grade BCL</td>
<td>Resection, chemoradiation, and ITC</td>
<td>No recurrence at 2 months</td>
</tr>
<tr>
<td>Bokhari et al., 2013 [11]</td>
<td>50/M</td>
<td>IC</td>
<td>Vomiting, nausea, headache, and confusion</td>
<td>DLBCL</td>
<td>Resection, chemoradiation, and ITC</td>
<td>No recurrence at 18 months</td>
</tr>
<tr>
<td>Rao et al., 2013 [12]</td>
<td>59/M</td>
<td>IC</td>
<td>Vomiting, nausea, vertigo, tremors of upper limbs and hands, and ataxia</td>
<td>DLBCL</td>
<td>Resection, chemotherapy</td>
<td>No recurrence at 8 months</td>
</tr>
<tr>
<td>Liao et al., 2014 [13]</td>
<td>77/M</td>
<td>IC</td>
<td>Vertigo, nausea, vomiting, and ataxia</td>
<td>DLBCL</td>
<td>Resection</td>
<td>No recurrence at 9 months</td>
</tr>
<tr>
<td>Fabiano et al., 2014 [14]</td>
<td>60/F</td>
<td>IC</td>
<td>Diplopia</td>
<td>DLBCL</td>
<td>Resection, chemoradiation, and ITC</td>
<td>No recurrence at 6 months</td>
</tr>
<tr>
<td>Grossman et al., 2014 [15]</td>
<td>66/M</td>
<td>IC</td>
<td>Ataxia, diplopia</td>
<td>PCNSL</td>
<td>Resection, unknown if further therapy</td>
<td>Unknown</td>
</tr>
<tr>
<td>Alabdulsalam et al., 2014 [16]</td>
<td>18/M</td>
<td>IC</td>
<td>Ataxia, cranial nerves IV, VII, IX, and X palsy</td>
<td>Burkitt</td>
<td>Resection, chemotherapy, and ITC</td>
<td>No recurrence at 18 months</td>
</tr>
<tr>
<td>Hsu et al., 2015 [17]</td>
<td>61/M</td>
<td>IC</td>
<td>Headache, dizziness, and ataxia</td>
<td>DLBCL</td>
<td>Resection, chemotherapy</td>
<td>No recurrence at 3 months</td>
</tr>
<tr>
<td>Suri et al., 2015 [18] \β</td>
<td>15/M</td>
<td>IC</td>
<td>Headache, nausea, vomiting, and generalized tonic clonic seizure</td>
<td>DLBCL</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Zhu et al., 2015 [19] \¥</td>
<td>66/M</td>
<td>IC</td>
<td>Headache, dizziness, diplopia, and cranial nerve VI, VII palsy</td>
<td>DLBCL</td>
<td>Chemotherapy</td>
<td>No recurrence at 6 months</td>
</tr>
<tr>
<td>Cellina et al., 2015 [20] \€</td>
<td>65/M</td>
<td>IC</td>
<td>Weight loss, headache, diplopia, and ataxia</td>
<td>DLBCL</td>
<td>Chemotherapy</td>
<td>No recurrence at 2 weeks</td>
</tr>
<tr>
<td>Liu et al., 2016 [21]</td>
<td>6/M</td>
<td>IC</td>
<td>Headache</td>
<td>Burkitt</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
<tr>
<td>Yi et al., 2017 [22]</td>
<td>61/M</td>
<td>IC</td>
<td>Headache, confusion, ataxia, and urinary incontinence</td>
<td>DLBCL</td>
<td>Resection, chemoradiation</td>
<td>No recurrence at 20 months</td>
</tr>
<tr>
<td>Current case \ψ</td>
<td>65/M</td>
<td>IC</td>
<td>Diplopia, vertigo, nausea, vomiting, weight loss, ataxia, and simple partial seizures</td>
<td>DLBCL</td>
<td>Chemoradiation, ITC</td>
<td>No recurrence at 8 months</td>
</tr>
</tbody>
</table>

(headache, nausea, and vomiting) (32-33%), and seizures (11-14%) [23, 24]. Imaging typically reveals a single brain lesion (66%), commonly in the supratentorial region (87%) [23]. Literature review of patients with 4th ventricular PCNSL indicates all patients were immunocompetent, had a median age of onset at 61-years-old, and had a male-to-female predominance (3.25:1) and intracranial metastatic disease in 35.3% of cases, with 50% of these documenting metastases to other ventricles (Table 1, Figure 4) [7–22].

PCNSL should be considered in any adult presenting with a 4th ventricular mass. Imaging may allude towards a PCNSL. CT may demonstrate hyper or isoattenuated lesions with marked contrast enhancement in immunocompetent PCNSL, whereas MRI may demonstrate isodense to hyperintense enhancement on T2-weighted imaging, with homogenous enhancement on T2-weighted imaging, with homogenous enhancement on T2-weighted imaging [25, 26]. In addition to neuroimaging, the PCNSL Collaborative Group recommends ruling out non-CNS disease with full-body PET imaging and bone marrow biopsy. The confirmatory diagnostic test of choice is a stereotactic biopsy. Macroscopically, PCNSL is often identified as a well-circumscribed mass [27]. Microscopically, the tumor has highly proliferative tumor cells with an angiocentric pattern with centroblastic or immunoblastic tumor cells within and around the cerebral blood vessels [24]. The majority of PCNSL are DLBCL (90%) and less commonly Burkitt’s lymphoma or T-cell lymphoma [6, 28]. Immunohistochemically, PCNSL cells stain positive for CD20 and Bcl-2 [24]. PCNSL cells are less frequently involved in translocations with IGH, BCL6, and MYC compared to systemic lymphomas [24].

While treatment of PCNSL has evolved in the past decade, many recommendations are derived from phase II clinical trials. In general, high-dose methotrexate (HD-MTX) and rituximab are recommended for initial induction agents due to improved overall response rates (ORR) and progression-free survival (PFS) [29]. Recently, the IELSG32 trial demonstrated that induction therapy with HD-MTX/leucovorin and rituximab with cytarabine improved the ORR (73 vs. 53%) and median PFS (20 months vs. 6 months) [30]. The multicenter cancer and leukemia group B study 50202 used rituximab, HD-MTX, and temozolomide followed by consolidation with high-dose etoposide and cytarabine with a reported ORR of 72% and PFS of 48 months, which is comparable to combination chemoradiation [28]. The Radiation Therapy Oncology Group 0227 trial (RTOG) used induction chemotherapy with rituximab, HD-MTX, and temozolomide followed by whole-brain radiation therapy (WBRT) and postirradiation temozolomide with an ORR of 86% and PFS of 90 months [31].

Both intrathecal chemotherapy (ITC) and surgical resection have been studied for the treatment of PCNSL, though routine use of either modality remains controversial. Despite the concern that CSF can harbor lymphoma cells and contribute to treatment failure or disease relapse [29], there has been no observed benefit of ITC on PFS or ORR in retrospective trials [32, 33]. In addition, surgical resection is not a recommended treatment modality due to the degree of tumor infiltration and risk of both postoperative neurologic damage and implantation metastasis associated with resection. Retrospective studies have not demonstrated a mortality benefit [23, 34], except for the German PCNSL study group 1 trial which reported improved OS in patients undergoing gross subtotal or total resection [35]. However, this advantage was lost when controlling for the total number of lesions [35]. Of patients with 4th ventricular PCNSL, 35.3% of patients received ITC [8–11, 14, 16], and 52.9% of patients with 4th ventricular PCNSL had gross subtotal or total resection [8, 11–17, 22]. These patients also received...
various combinations of chemotherapy and chemoradiation so whether either of these treatment modalities conferred a survival benefit in this select patient population is not known.

4. Conclusion

PCNSL arising from the 4th ventricle is a rare occurrence that is seldom described in the literature. This case provides further evidence that PCNSL is often a malignancy of immunocompetent males. Due to its uncommon occurrence, it is unknown if commonly utilized treatment modalities that are employed in other anatomic variants of PCNSL will have similar impact on overall survival and progression-free survival. While surgical resection has been used in over half of 4th ventricular PCNSL, it is unknown how this impacted OS or PFS. Further research is needed to determine the optimal treatment for the many variants of PCNSL, which may vary by location or tumor subtype.

Abbreviations

MRI: Magnetic resonance imaging  
DLBCL: Diffuse large B-cell lymphoma  
PCNSL: Primary CNS lymphoma  
NHL: Non-Hodgkin lymphoma  
LDH: Lactate dehydrogenase  
CT: Computed tomography  
PET: Positron emission tomography  
Hyper-CVAD: Cyclophosphamide, vincristine, doxorubicin, and dexamethasone  
CSF: Cerebrospinal fluid  
ITC: Intrathecal chemotherapy  
PFS: Progression-free survival  
ORR: Overall response rate  
OS: Overall survival  
MRV: Magnetic resonance venography

Conflicts of Interest

The authors have no conflicts of interest to declare.

References


